Literature DB >> 16880239

RFA for liver tumors: does it really work?

Heather Higgins1, David L Berger.   

Abstract

The use of radiofrequency ablation (RFA) is increasing in the treatment of both primary and metastatic hepatic tumors. However, the role of RFA has yet to be clearly defined in patients who are still considered amenable to surgical intervention. Future prospective studies are needed to define whether RFA can be used as an alternative to surgery in certain patient populations. In the interim, radiofrequency ablation technology will continue to advance and serve as both a palliative and potentially curative intervention for individuals with hepatic tumors.

Entities:  

Mesh:

Year:  2006        PMID: 16880239     DOI: 10.1634/theoncologist.11-7-801

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  8 in total

1.  Incorporation of preprocedural PET into CT-guided radiofrequency ablation of hepatic metastases: a nonrigid image registration validation study.

Authors:  Peng Lei; Omkar Dandekar; David Widlus; Raj Shekhar
Journal:  J Digit Imaging       Date:  2009-05-27       Impact factor: 4.056

2.  The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy-a case matched study.

Authors:  C Nicholas Kotewall; Tan To Cheung; Wong Hoi She; Ka Wing Ma; Simon Hing Ying Tsang; Jeff Wing Chiu Dai; Albert Chi Yan Chan; Kenneth Siu Ho Chok; Chung Mau Lo
Journal:  Transl Gastroenterol Hepatol       Date:  2017-04-28

3.  Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study.

Authors:  Qiao Zhang; Feng Xia; Hengyi Gao; Zhenheng Wu; Wenjing Cao; Qingfeng Xiang; Zhifeng Guan; Yang Su; Weiqiao Zhang; Weiqiang Chen; Ali Mo; Shuqun Li
Journal:  Front Surg       Date:  2022-06-20

4.  Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Authors:  Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

5.  Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases.

Authors:  Kyung Ho Kim; Yong Sik Yoon; Chang Sik Yu; Tae Won Kim; Hye Jin Kim; Pyo Nyun Kim; Hyun Kwon Ha; Jin Cheon Kim
Journal:  J Korean Surg Soc       Date:  2011-07-11

6.  Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.

Authors:  Mostafa Mohamed; Alan W Katz; Mohamedtaki A Tejani; Ashwani K Sharma; Randeep Kashyap; Marcus S Noel; Haoming Qiu; Aram F Hezel; Gopal A Ramaraju; M Katherine Dokus; Mark S Orloff
Journal:  Adv Radiat Oncol       Date:  2015-12-29

7.  Sedation and Analgesia for Liver Cancer Percutaneous Radiofrequency Ablation: Fentanyl and Oxycodone Comparison.

Authors:  Jiangling Wang; Xiaohong Yuan; Wenjing Guo; Xiaobin Xiang; Qicheng Wu; Man Fang; Wen Zhang; Zewu Ding; Kangjie Xie; Jun Fang; Huidan Zhou; Shuang Fu
Journal:  Int J Med Sci       Date:  2020-08-12       Impact factor: 3.738

8.  Different effects of oxycodone and remifentanil in patients undergoing ultrasound-guided percutaneous radiofrequency ablation of hepatic cancer: a randomized trial.

Authors:  Junbei Wu; Yunhong Lu; Xiaofei Cao
Journal:  Drug Des Devel Ther       Date:  2019-01-18       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.